to Assess the effect of Virechana and Basti karma treatment in patients of Metabolic dysfunction associated Non alcoholic fatty liver disease.

Assessment of effect of Dashamooladi Kshara Basti and Dashamooladi Yoga Basti with Virechana karma in the management of Metabolic dysfunction associated steatotic liver disease (MASLD) An open labelled randomized comparative clinical trial. - MASLD

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086840

Enrollment

100

Registered

2025-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E788- Other disorders of lipoprotein metabolism

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Previously diagnosed cases or freshly diagnosed cases of MASLD presence of accumulation of fatty tissue on liver confirmed by Ultrasonography Abdomen finding suggestive of grade 1 2 3 with hepatorenal index. And presence of at least one cardio metabolic risk factors BMI more than or equal to 24kg perm2 or Waist circumference more than or equal to 90 cm in male and 80 cm in female. Fasting serum glucose more than or equal to 5.6 mmol per L or 2hour post load glucose levels more than or eqal to7.8mmolper L Blood pressure more than or equal to 130by85 mmHg Plasma triglycerides more than or equal to 1.70mmoL Plasma HDL less than or equal to 1mmolperL in male and less than or equal to 1.3mmolperL in female

Exclusion criteria

Exclusion criteria: Patients who are Contraindicated for Virechana and Basti Karma. Patients having suffering from AIDS T.B Malignancies other infectious disease. Patients suffering from Liver cirrhosis Hepatitis hepatocellular carcinoma Ascites Cholecystitis Cholelithiasis Hypothyroidism. Patients who consuming Alcohol or other narcotic substances. Pregnant or Lactating women.

Design outcomes

Primary

Measure	Time frame
Changes in Lipid profile. Changes in Apolipoprotein B level Small dense low density lipoprotein level (Sd LDL) Timepoint: out come will be assesed after completion of treatment (approx after 28 days)	—

Secondary

Measure	Time frame
Changes in Body weight waist circumference. Changes in Ultrasonography of Fatty liver gradation with Hepatorenal index Reduction in Hepatic profile. Changes in Systolic & Diastolic Blood pressure. Changes in Blood glucose levels. To improvement in quality of life of patients having MASLD assessed by CLDQ (Chronic liver disease questionnaire)Timepoint: out come will be assess after completion of treatment (Approx after 28 days)	—

Measure

Time frame

Changes in Body weight waist circumference. Changes in Ultrasonography of Fatty liver gradation with Hepatorenal index Reduction in Hepatic profile. Changes in Systolic & Diastolic Blood pressure. Changes in Blood glucose levels. To improvement in quality of life of patients having MASLD assessed by CLDQ (Chronic liver disease questionnaire)Timepoint: out come will be assess after completion of treatment (Approx after 28 days)

—

Countries

India

Contacts

Public Contacthiral patel

Institute of teaching and research in ayurveda jamnagar

neha@itra.edu.in9601796503

Outcome results